GLOBAL LIVER INSTITUTE
Global Fatty Liver Day, formerly known as International NASH Day, is a public education campaign that was inaugurated in June 2018 to enhance awareness and emphasize the pressing nature of fatty liver disease, particularly its advanced stages.
As prospects for new fatty liver and NASH treatments appear on the horizon, GLI continues to push for better awareness, screening, and treatment options. With fatty liver disease being diagnosed in a growing pediatric population, understanding the role of nutrition, risks, and the connection to co-occurring disorders is vital to addressing this chronic, progressive disease.
As the field of NASH is on the verge of clinical and diagnostic breakthroughs, discover how GLI is promoting healthier living through our personalized nutrition solution, advocating for greater inclusion in clinical trials, and recognizing the role of drug safety and efficacy.
The 6th International NASH Day was a resounding global success, with over 100 partners from 55 countries participating.
GLI to Address Need for NAFLD/NASH Nomenclature Implementation Plan Since the joint medical society announcement of the change in nomenclature for NAFLD at the recent International Liver...
Today is International NASH Day, a time where healthcare experts and community members around the globe step up and raise awareness of the most common liver disease in the world – nonalcoholic fatty liver disease (NAFLD) – and it’s more severe form, nonalcoholic steatohepatitis (NASH).
How do you plan to #StepUpforNASH? Learn more about how you can get involved today!
Despite acknowledging OCA met the endpoint established by the FDA of reducing fibrosis by at least one stage, GIDAC voted against approval for treatment for NASH.
It is more crucial than ever to not only understand the latest developments in the field but also play an active role in them.
At GLI, we believe in creating solutions for patients at every stage of their care pathway.
Let’s Step Up for NASH this June and raise awareness about nonalcoholic fatty liver disease (NAFLD) and its more advanced form, nonalcoholic steatohepatitis (NASH), in your communities.
With the NASH horizon full of new developments, it is important to maintain focus on high-quality, affordable, and equitable care for patients with NAFLD and NASH.
